COMPOSITIONS AND METHODS TO MODULATE ANGIOGENESIS
The present invention provides methods of stimulating angiogenesis and the growth or migration of cells associated with angiogenesis, by contacting animals, tissues, or cells with sulfide, alone or in combination with nitric oxide. These methods may be used for a variety or purposes, including promoting wound healings, increasing blood flow, and for the treatment and prevention of diseases and disorders associated with decreased blood flow, including ischemic or hypoxic injury.
1 . A method of stimulating angiogenesis in an animal, tissue or organ, comprising administering to the animal, tissue or organ an effective amount of sulfide.
2 . The method of claim 1 , wherein said sulfide is administered in a stable liquid pharmaceutical composition comprising said sulfide and a pharmaceutically acceptable carrier, and wherein the concentration, pH, and oxidation products of said sulfide remain within a range of acceptance criteria after storage of said liquid pharmaceutical composition.
3 . The method of claim 1 , comprising administering to the animal, tissue organ the effective amount of sulfide in combination with an effective amount of nitric oxide.
4 - 10 . (canceled)
11 . The method of claim 2 , wherein said animal is a mammal or said tissue or organ is a mammalian tissue or organ.
12 . (canceled)
13 . A method for promoting wound healing in an animal, comprising administering to the animal an effective amount of sulfide, alone or in combination with an effective amount of nitric oxide.
14 . The method of claim 13 , wherein said sulfide is administered locally, intradermally, intraperitoneally, subcutaneously, or topically.
15 . The method of claim 13 , wherein said wound healing comprises re-epithelialization of a denuded area of skin of an animal after a burn, trauma, wound, injury, chemotherapy, skin reaction following drug treatment or disease process.
16 . (canceled)
17 . A method for treating or preventing an injury or disease associated with decreased or insufficient blood flow in an animal, comprising administering to said animal an effective amount of sulfide, alone or in combination with an effective amount of nitric oxide.
18 . The method of claim 17 , wherein said animal is a mammal.
19 - 21 . (canceled)
22 . The method of claim 17 , wherein said decreased or insufficient blood flow is cerebral blood flow.
23 . The method of claim 17 , wherein said decreased or insufficient blood flow is localized within said animal.
24 . The method of claim 17 , wherein said injury or disease is diabetic foot ulcers.
25 . The method of claim 17 , wherein said injury or disease is peripheral vascular disease.
26 . The method of claim 17 , wherein said injury or disease is a coronary injury or disease selected from the group consisting of: congestive heart failure, myocardial ischemia, coronary artery disease, and angina.
27 . The method of claim 17 , wherein said disease is an ocular disease.
28 - 29 . (canceled)
30 . The method of claim 2 , wherein the stable liquid pharmaceutical composition is prepared by dissolving one equivalent of hydrogen sulfide gas into one equivalent of sodium hydroxide solution, wherein said composition has a pH in the range of 6.5 to 8.5, wherein said composition has an osmolarity in the range of 250-330 mOsmol/L, wherein said composition has an oxygen content of less than or equal to 5 μM, and wherein said composition comprises oxidation products are the range of 0%-3.0% (w/v) after storage for three months.
31 . The method of claim 30 , wherein said sulfide is administered intravenously.